NLRP3 and Sepsis: Simultaneous blockade of the HMGB1—TLR4 axis (e.g., via neutralizing antibodies) and the NLRP3 inflammasome (e.g., using MCC950) can decrease the secretion of IL—1β in experimental sepsis models.